CE for Nurses
In the past decade, the treatment landscape for multiple myeloma (MM) has significantly improved with the introduction of several novel treatment regimens. Oncology nurses are constantly challenged to stay up-to-date with these recent advances in the management of MM.
View these additional Nursing activities
ASCO 2018 Annual Meeting Highlights in Multiple Myeloma
EHA 2018 Annual Congress Highlights in Multiple Myeloma
Challenging Cases in RRMM Symposium Replay
Developing Care Plans for Treatment-based Patient Monitoring in Relapsed/Refractory Multiple Myeloma
|Maintenance Therapy and Sequencing Treatment in Multiple Myeloma|
Paul G. Richardson, MD; Sarah A. Holstein, MD, PhD
|Release Date: January 16, 2019|
Expiration Date: January 16, 2020
Many patients with multiple myeloma (MM) will relapse after treatment, even after receiving standard-of-care therapy. Initiating maintenance treatment after autologous stem cell transplantation has the potential to benefit patients and may reduce risks for the development of relapsed/refractory MM. For those who relapse or become refractory to treatment, novel therapies and sequenced treatment approaches are being utilized to improve patient outcomes.
As MM treatment strategies continue to evolve, oncology nurses must remain current with recent therapeutic advances. In their efforts to optimize supportive care, nurses must ensure that patients understand the importance of maintenance therapy and be educated on why they may receive sequenced treatment and what to expect regarding efficacy and potential adverse events.
In this activity, Dr. Sarah Holstein describes the role of maintenance therapy in MM as well as efficacy and safety of emerging maintenance treatments. Dr. Paul Richardson discusses efficacy and safety data for new therapies for relapsed/refractory disease and provides strategies for making risk-adapted treatment decisions.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
|Begin, Earn CreditView Only, No Credit|
|Supportive Care Strategies for Managing Newly Diagnosed Multiple Myeloma|
Philip L. McCarthy, MD, and Shaji K. Kumar, MD
|Release Date: September 28, 2018|
Expiration Date: September 28, 2019
The treatment landscape for multiple myeloma (MM) continues to evolve, largely because of improvements in diagnosing the disease and advances in treatment for newly diagnosed patients. Oncology nurses are constantly challenged to stay
To appropriately manage NDMM, a full patient workup using guideline-based testing strategies and key laboratory tests is required. Patients must understand the impact of myeloma-defining events on determining when treatment will be started. In addition, nurses are at the forefront of providing supportive care to NDMM patients when new therapies and treatment plans are initiated. They must balance potential benefits with tolerability and risks for side effects.
In this activity, Dr. Philip McCarthy outlines important steps for accurately diagnosing patients with suspected MM, and strategies for using that information to develop effective, individualized treatment regimens. Dr. Kumar discusses important considerations when using novel therapies in NDMM, including comorbidities and treatment-related adverse events. These factors must be appropriately assessed and monitored to optimize safety and prevent premature discontinuation of therapy.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
|Begin, Earn CreditView Only, No Credit|
|Frontline Treatment in Multiple Myeloma: Treating the Individual Patient|
R. Donald Harvey, III, PharmD, BCOP, FCCP, FHOPA and Sagar Lonial, MD, FACP
|Release Date: January 10, 2018|
Expiration Date: January 10, 2019
In recent years, advances in treatment have resulted in significantly improved outcomes and prognoses in patients with multiple myeloma; much of this research, however, was focused on the population of patients with relapsed or refractory disease. Today, a growing compendium of data and ongoing research is evaluating treatment options and management approaches specifically in patients with newly diagnosed multiple myeloma. The addition of new lenalidomide- and bortezomib-based drug regimens for patients with multiple myeloma increases the complexity of pharmacotherapeutic strategies, which must balance response benefit with tolerability. In addition, there are a number of comorbidities and treatment-related adverse events that must be appropriately assessed and monitored for, to ensure patient safety and prevent premature discontinuation of therapy. In these activities, Dr. Lonial and Dr. Harvey provide an overview of the current and emerging frontline treatment paradigms for multiple myeloma, and discuss how to provide individualized care for patients with comorbid conditions.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology
|View Only, CE ExpiredView Only, No Credit|